Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search
Clear, colourless, sterile eye drops containing Chloramphenicol PhEur 0.5% w/v.
Sterile single use eye drop.
Chloramphenicol is indicated for the topical treatment of infections due to micro-organisms sensitive to the anti-infective.
Adults (including the Elderly) and Children
One to two drops applied topically to each affected eye up to six times daily or more frequently if required. (Severe infections may require one to two drops every fifteen to twenty minutes initially, reducing the frequency of instillation gradually as the infection is controlled).
Use in patients with a history of hypersensitivity or toxicity to chloramphenicol or any other component of the preparation.
In severe infections topical use of chloramphenicol should be supplemented with appropriate systemic treatment.
Aplastic anaemia has, very rarely, followed topical use of chloramphenicol eye drops and, whilst this hazard is an uncommon one, it should be borne in mind when the benefits of the use of chloramphenicol are assessed.
Prolonged use should be avoided as it may increase the likelihood of sensitisation and the emergence of resistant organisms.
Chloramphenicol should be reserved for use only in infections for which it is specifically indicated.
Contact lenses should be removed during the period of treatment.
Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of the drops via the naso lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children.)
Chymotrypsin will be inhibited if given simultaneously with chloramphenicol.
Safety for use in pregnancy and lactation has not been established, therefore, use only when considered essential by the physician.
May cause transient blurring of vision on instillation. Warn patients not to drive or operate hazardous machinery unless vision is clear.
Local
Sensitivity reactions such as transient irritation, burning, stinging, itching and dermatitis, may occasionally occur.
Systemic
Rarely, cases of major adverse haematological events (bone marrow depression, aplastic anaemia and death) have been reported following ocular use of chloramphenicol.
Not applicable.
Chloramphenicol is an antibiotic which is mainly bacteriostatic in action, but exerts a bactericidal effect against some strains of gram-positive cocci and against Haemophilus Influenzae and Neisseria. It has a broad spectrum of action against both gram-positive and gram-negative bacteria, rickettsiae and chlamydia.
Chloramphenicol binds specifically to the 50s subunit of 70s ribosomes, preventing its movement along messenger RNA, which occurs in the early stages of protein synthesis.
Chloramphenicol also inhibits NADH oxidase, affecting the mitochondrial respiratory chain.
In a study in patients, instillation of chloramphenicol eye drops to the eye (2 drops of a 0.5% solution instilled every 5 minutes for a total of 6 doses, into the eyes of 14 patients) gave concentrations of chloramphenicol of 3.5 - 6.7mcg/ml in the aqueous humour.
Chloramphenicol is rapidly absorbed after oral administration. In the liver, chloramphenicol is inactivated by conjugation with glucuronic acid or by reduction to inactive aryl amines. Excretion is mainly renal, though some bile excretion occurs following oral administration.
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the data sheet.
Borax PhEur
Boric acid PhEur
Purified water PhEur
None known.
30 months.
Store between 2° and 8°C. Do not freeze. Protect from light.
Prescription medicine.
A sealed conical shaped polypropylene container fitted with a twist and pull off cap. Each Minims unit is overwrapped in an individual polypropylene/paper pouch.
Each Minims unit should be discarded after a single use.
Bausch & Lomb (NZ) Ltd
c/o New Zealand Medical & Scientific
2a Fisher Crescent
Mt Wellington
Auckland
NEW ZEALAND
4 October 2006